AKT-IN-3

AKT-IN-3 (compound E22) is a potent, orally active low hERG blocking Akt inhibitor, with 1.4 nM, 1.2 nM and 1.7 nM for Akt1, Akt2 and Akt3, respectively. AKT-IN-3 (compound E22) also exhibits good inhibitory activity against other AGC family kinases, such as PKA, PKC, ROCK1, RSK1, P70S6K, and SGK. AKT-IN-3 (compound E22) induces apoptosis and inhibits metastasis of cancer cells[1].

Product Specifications

CAS Number

[2374740-21-1]

UNSPSC

12352005

Target

Akt; Apoptosis

Type

Reference compound

Related Pathways

Apoptosis; PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/akt-in-3.html

Purity

98.12

Solubility

DMSO : ≥ 100 mg/mL

Smiles

CNC(C[C@H]1NC[C@@H](NC(C2=CC(C3=C(Cl)C=NN3C)=C(Cl)O2)=O)[C@H](C4=CC(F)=C(F)C=C4)C1)=O

Molecular Formula

C23H23Cl2F2N5O3

Molecular Weight

526.36

References & Citations

[1]Dong X, et al. Discovery of 3,4,6-Trisubstituted Piperidine Derivatives as Orally Active, Low hERG Blocking Akt Inhibitors via Conformational Restriction and Structure-Based Design. J Med Chem. 2019 Aug 8;62 (15) :7264-7288.